Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injectafer in RLS
NCT02397057Phase 3Completed
- Sponsor
- American Regent, Inc.
- Start
- Jan 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in restless legs syndrome (RLS) comparing Injectafer with Placebo (2 arms). Primary endpoints: International Restless Legs Syndrome Total Score Change From Baseline at Day 42 and Proportion of Patients Rated as Much or Very Much Improved With the Clinical Global Impression - Improvement at Day 42. Started Jan 2015; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT02397057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02397057.